B. Riley Has Strong Forecast for Agenus FY2029 Earnings

Agenus Inc. (NASDAQ:AGEN) – Equities researchers at B. Riley upped their FY2029 EPS estimates for Agenus in a research note issued on Monday, April 21st. B. Riley analyst M. Mamtani now forecasts that the biotechnology company will earn $0.38 per share for the year, up from their previous estimate of $0.29. B. Riley currently has a “Buy” rating on the stock. The consensus estimate for Agenus’ current full-year earnings is ($12.55) per share.

Agenus (NASDAQ:AGEN) last released its quarterly earnings data on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.36) by $0.32. The business had revenue of $26.84 million during the quarter, compared to the consensus estimate of $30.09 million.

A number of other equities analysts have also weighed in on the company. StockNews.com raised Agenus from a “sell” rating to a “hold” rating in a research report on Friday, March 21st. Robert W. Baird reduced their price target on shares of Agenus from $6.00 to $3.00 and set a “neutral” rating for the company in a research note on Wednesday, March 12th. Finally, HC Wainwright restated a “neutral” rating on shares of Agenus in a research report on Tuesday, March 18th. Six equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $8.75.

Agenus Price Performance

Shares of NASDAQ:AGEN opened at $2.85 on Wednesday. Agenus has a 1 year low of $1.38 and a 1 year high of $19.69. The company has a market cap of $72.13 million, a P/E ratio of -0.25 and a beta of 1.58. The stock’s fifty day moving average price is $2.16 and its 200-day moving average price is $3.07.

Institutional Investors Weigh In On Agenus

A number of large investors have recently made changes to their positions in the company. Corton Capital Inc. purchased a new position in shares of Agenus in the fourth quarter worth approximately $36,000. Virtu Financial LLC bought a new position in Agenus in the fourth quarter worth approximately $51,000. Apollon Wealth Management LLC purchased a new position in shares of Agenus during the 4th quarter worth $55,000. Bank of Montreal Can bought a new stake in shares of Agenus during the 4th quarter valued at $69,000. Finally, Barclays PLC increased its stake in shares of Agenus by 17.7% in the 4th quarter. Barclays PLC now owns 32,737 shares of the biotechnology company’s stock worth $90,000 after purchasing an additional 4,924 shares in the last quarter. 61.46% of the stock is currently owned by institutional investors.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.